|
The table below presents common shares underlying stock options and warrants that
are excluded from the calculation of the weighted average number of common shares
outstanding used for the calculation of diluted net loss per common share. These are
excluded from the calculation due to their anti-dilutive effect:
| Schedule of antidilutive securities excluded from computation of net loss per common share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended |
|
|
Nine Months Ended |
|
| |
|
September 30, |
|
|
September 30, |
|
| (in thousands) |
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
| Weighted-average anti-dilutive common shares resulting from convertible preferred stock |
|
|
3,767 |
|
|
|
- |
|
|
|
1,269 |
|
|
|
- |
|
| Weighted-average anti-dilutive common shares resulting from convertible notes |
|
|
504 |
|
|
|
- |
|
|
|
170 |
|
|
|
- |
|
| Weighted-average anti-dilutive common shares resulting from options |
|
|
1,861 |
|
|
|
932 |
|
|
|
1,241 |
|
|
|
975 |
|
| Weighted-average anti-dilutive common shares resulting from warrants |
|
|
9,818 |
|
|
|
4,933 |
|
|
|
7,678 |
|
|
|
5,586 |
|
| |
|
|
15,950 |
|
|
|
5,865 |
|
|
|
10,358 |
|
|
|
6,561 |
|
|